Inhibrx Biosciences Inc (INBX): Price-to-Revenue Ratio

Brandmark of Inhibrx Corp (INBX)

The price-to-sales multiple on GURU.Markets reflects the market valuation of Inhibrx Biosciences (INBX), where the value 1091.60 corresponds to the current metric. This trend is driven by a robust R&D pipeline of protein candidates. Efficient cash management following the deal with Sanofi supports development, although geopolitical instability and logistical collapse hinder international trials of drugs for the treatment of rare pathologies.

INBX Inhibrx Biosciences P/S Multiple (07/04/2022 - 08/14/2026)

Inhibrx Biosciences Inc (INBX) - metric breakdowns and financial figures

- current quotes and average value forecast:
Market Price inhibrx.com|INBX - Price Target Chart
- stock exchange capitalization data:
Market Value Inhibrx Biosciences Inc|INBX - Total Company Value
- issuer book value statistics:
Net Asset Value per Share Inhibrx Biosciences|INBX - Book Capitalization|Market Value to Equity Ratio inhibrx.com|INBX - Cumulative Company Assets
- issuer credit burden and liquidity indicators:
Debt to Capital Inhibrx Biosciences|INBX - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital Inhibrx Corp|INBX - Company Total Debt|Debt to Book Capital Inhibrx Biosciences Inc|INBX - Company Long-Term Debts|Company Short-Term Loans and Borrowings Inhibrx Biosciences|Immediate Liquidity inhibrx.com
- earnings and multiples data:
INBX - Company Net Income|Expected Net Income Inhibrx Biosciences|INBX - P/E Multiple|Forward P/E Multiple Inhibrx|INBX - Price/Earnings to Growth Ratio|Company Value to Operating Income Before Depreciation Ratio Inhibrx Biosciences Inc|INBX - Operating profit before deduction of amortization|Net earnings per one share for the last twelve months Inhibrx Biosciences|INBX - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months inhibrx.com|INBX - Earnings per share growth in current year|Projected earnings per share growth rate for next year Inhibrx Biosciences
- issuer revenue and sales details:
INBX - Revenue and Sales Volume|Company Future Revenue inhibrx.com|INBX - P/S Multiple|Market Cap to Expected Sales Ratio Inhibrx Biosciences Inc
Summary company analytics:inhibrx.com
Mass-produced product of Inhibrx Corp

An investment audit of Inhibrx Biosciences (INBX) requires an analysis of the market capitalization to annual revenue ratio, which determines the value of every dollar of the business's sales. This calculated P/S reflects market expectations for the scaling of robotic laboratories searching for biomolecules, helping investors differentiate fundamental undervaluation from stagnation risks through the price action on this chart.

Competing companies

INCY - Price to Sales|Price-to-Revenue Ratio HUTCHMED HCM|Nuvation Bio Inc - Price-to-Revenue Ratio|DAWN - Price-to-Revenue Ratio|Price to Sales Monopar Corp|IMAB: P/S Multiple|Price-to-Revenue Multiple fennecpharma.com FENC|Market Cap to Revenue HRTX|Price to Sales Nuvectis Pharma Inc. NVCT|Market Cap to Revenue CHRS (Coherus)|CRBP (Corbus Pharmaceuticals, Inc.) - Market Capitalization-to-Revenue Ratio|Cardiff Oncology - Market Cap to Revenue|Market Cap to Sales Volume BYSI (beyondspringpharma.com)|BioAtla Corp - P/S Multiple|Market Capitalization-to-Revenue Ratio LIXT (Lixte Biotechnology Holdings Inc.)|CTXR: P/S Multiple|Price to Sales Cellectar Corp (CLRB)|Price-to-Revenue Ratio BioLineRx Ltd.|CANF: Market Capitalization-to-Revenue Ratio|P/S Multiple APRE|P/S Multiple kaziatherapeutics.com (KZIA)|Price-to-Revenue Ratio Silexion Therapeutics SLXN|NCNA (NuCana PLC) - Price-to-Sales Ratio|CMRX: Market Cap to Revenue|Price to Sales cyclacel.com|GTHX: P/S Multiple|KRON - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Kintara|Market Cap to Revenue Ratio ONCT (Oncternal Corp)|P/S Multiple PRTG